-
1.发明申请公开(公告)号：US20110212899A1
公开(公告)日：2011-09-01
申请号：US11578796
申请日：2005-04-21
申请人： Yoshiko Takayama , Yoshikuni Nakamura , Yutaka Inoue , Chiho Yabuta , Mitsuyoshi Azuma , Satomi Onoue
发明人： Yoshiko Takayama , Yoshikuni Nakamura , Yutaka Inoue , Chiho Yabuta , Mitsuyoshi Azuma , Satomi Onoue
CPC分类号： A61K38/2278
摘要： It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This agent for promoting corneal neuritogenesis is useful as a drug for ameliorating reduction in corneal sensitivity following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal sensitivity accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal sensitivity. Moreover, it is useful as a drug for ameliorating dry eye symptom, reduction in corneal sensitivity and corneal epithelial injury in patients with dry eye, and a drug for ameliorating corneal epithelial injury and dry eye symptom and reduction in corneal sensitivity accompanying therewith.
摘要翻译： 旨在提供用于促进包含PACAP，PACAP衍生物或其药学上可接受的盐的角膜神经发生的药剂，特别是用于促进角膜神经突发生的药物，其目的在于改善角膜敏感性，治疗干眼症并治疗角膜上皮损伤 促进角膜神经发生的作用。 用于促进角膜神经发生的药物可用作改善角膜手术如角膜手术（LASIK）和角膜移植术或白内障手术后角膜敏感性降低的药物，伴随角膜神经变性和干眼症状以及角膜上皮损伤伴随的角膜敏感性降低 角膜敏感度降低。 此外，它可用作改善干眼症状，减少干眼症患者的角膜敏感性和角膜上皮损伤的药物，以及用于改善角膜上皮损伤和干眼症状以及与之伴随的角膜敏感性降低的药物。
-
公开(公告)号：US09517204B2
公开(公告)日：2016-12-13
申请号：US14344467
申请日：2012-09-13
申请人： Satomi Onoue , Shizuo Yamada
发明人： Satomi Onoue , Shizuo Yamada
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/145 , A61K9/146 , A61K31/4418 , A61K47/26 , A61M11/002 , A61M15/00 , A61M2202/064
摘要： The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same.Said powder formulation makes inhalation therapy possible by carrying out aerosolization easily, and since pharmacological effect in lung local part is increased, it is possible to decrease the dose. Skin transmigration of said medicine is controlled by a lung specific delivery technology, and photodermatosis which is a side effect can be controlled.
摘要翻译： 所述粉末制剂可以容易地进行雾化，可以进行吸入治疗，并且由于肺局部部位的药理作用增加，因此可以降低剂量。 所述药物的皮肤转移由肺特异性递送技术控制，并且可以控制作为副作用的光皮质病变。
-
公开(公告)号：US20140341998A1
公开(公告)日：2014-11-20
申请号：US14344467
申请日：2012-09-13
申请人： Satomi Onoue , Shizuo Yamada
发明人： Satomi Onoue , Shizuo Yamada
IPC分类号： A61K9/14 , A61K47/26 , A61K31/4418
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/145 , A61K9/146 , A61K31/4418 , A61K47/26 , A61M11/002 , A61M15/00 , A61M2202/064
摘要： The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same.Said powder formulation makes inhalation therapy possible by carrying out aerosolization easily, and since pharmacological effect in lung local part is increased, it is possible to decrease the dose. Skin transmigration of said medicine is controlled by a lung specific delivery technology, and photodermatosis which is a side effect can be controlled.
摘要翻译： 本发明涉及减少具有药物诱导的光皮质病的副作用的药物的副作用风险并增加治疗效果的粉末制剂，并涉及其制备方法。 所述粉末制剂可以容易地进行雾化，可以进行吸入治疗，并且由于肺局部部位的药理作用增加，因此可以降低剂量。 所述药物的皮肤转移由肺特异性递送技术控制，并且可以控制作为副作用的光皮质病变。
-
公开(公告)号：US07459441B2
公开(公告)日：2008-12-02
申请号：US10494634
申请日：2002-11-05
申请人： Yoko Minagawa , Atsuko Fujii , Yukuo Yoshida , Satomi Onoue , Kazuhisa Kashimoto
发明人： Yoko Minagawa , Atsuko Fujii , Yukuo Yoshida , Satomi Onoue , Kazuhisa Kashimoto
IPC分类号： A61K38/00
CPC分类号： A61K9/0048 , A61K38/00 , A61K47/42 , C07K14/57563
摘要： Remedies for dry eye and diseases associated with dry eye which contain as the active ingredient peptides represented by the general formula (I): H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-X1-Gln-X2-Ala-Val-X3-X4-Tyr-Leu-X5-X6(SEQ ID NOS: 26-36) (I) wherein X1, X3 and X4 represent Lys or Arg, respectively; X2 represents Met, Leu or nLeu; X5 represents a chemical bond, Asn, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Ile-Leu(SEQ ID NO: 37) or Asn-Ser-Ile-Leu-Asn-X7(SEQ ID NOS: 38-43) (wherein X7 represents a chemical bond, Gly, etc.); and X6 represents —OH or —NH2, or pharmaceutically acceptable salts thereof:.
摘要翻译： 作为活性成分的由通式（I）表示的肽的干眼症和与干眼症相关的疾病的补救措施：<？in-line-formula description =“In-line Formulas”end =“lead”？> H- His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-X1-Gln-X2-Ala-Val-X3-X4-Tyr-Leu-X5-X6 SEQ ID NO：26-36）（I）<？in-line-formula description =“In-line Formulas”end =“tail”？>其中X1，X3和X4分别表示Lys或Arg; X2表示Met，Leu或nLeu; X5表示化学键，Asn，Asn-Ser，Asn-Ser-Ile，Asn-Ser-Ile-Leu（SEQ ID NO：37）或Asn-Ser-Ile-Leu-Asn-X7（SEQ ID NO：38 -43）（其中X7表示化学键，Gly等）; X 6表示-OH或-NH 2，或其药学上可接受的盐。
-
公开(公告)号：US07332473B2
公开(公告)日：2008-02-19
申请号：US10536880
申请日：2003-11-21
申请人： Satomi Onoue , Kousuke Endo , Asami Matsumoto
发明人： Satomi Onoue , Kousuke Endo , Asami Matsumoto
CPC分类号： C07K14/57563 , A61K38/00
摘要： This invention provides a pharmaceutical composition comprising, as an active ingredient, a peptide derived from a PACAP or VIP peptide or a pharmaceutically acceptable salt thereof. This invention provides a PACAP/VIP derivative that can inhibit tautomerization in a solution and that can be applied to clinical applications over a long period of time. Such peptides are useful for ameliorating symptoms of diseases, such as regressive neurodegenerative diseases, erectile dysfunction, and bronchial asthma.
摘要翻译： 本发明提供一种药物组合物，其包含源自PACAP或VIP肽或其药学上可接受的盐作为活性成分的肽。 本发明提供了可以抑制溶液中互变异构化并可长期应用于临床应用的PACAP / VIP衍生物。 这些肽可用于改善诸如退行性神经变性疾病，勃起功能障碍和支气管哮喘等疾病的症状。
-
公开(公告)号：US20060276384A1
公开(公告)日：2006-12-07
申请号：US10536880
申请日：2003-11-21
申请人： Satomi Onoue , Kousuke Endo , Asami Matsumoto
发明人： Satomi Onoue , Kousuke Endo , Asami Matsumoto
CPC分类号： C07K14/57563 , A61K38/00
摘要： This invention provides a pharmaceutical composition comprising, as an active ingredient, a peptide derived from a PACAP or VIP peptide or a pharmaceutically acceptable salt thereof. This invention provides a PACAP/VIP derivative that can inhibit tautomerization in a solution and that can be applied to clinical applications over a long period of time. Such peptides are useful for ameliorating symptoms of diseases, such as regressive neurodegenerative diseases, erectile dysfunction, and bronchial asthma.
摘要翻译： 本发明提供一种药物组合物，其包含源自PACAP或VIP肽或其药学上可接受的盐作为活性成分的肽。 本发明提供了可以抑制溶液中互变异构化并可长期应用于临床应用的PACAP / VIP衍生物。 这些肽可用于改善诸如退行性神经变性疾病，勃起功能障碍和支气管哮喘等疾病的症状。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.028 秒)
